1. Home
  2. MURA vs NSPR Comparison

MURA vs NSPR Comparison

Compare MURA & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MURA
  • NSPR
  • Stock Information
  • Founded
  • MURA 2013
  • NSPR 2005
  • Country
  • MURA Ireland
  • NSPR Israel
  • Employees
  • MURA N/A
  • NSPR N/A
  • Industry
  • MURA
  • NSPR Medical/Dental Instruments
  • Sector
  • MURA
  • NSPR Health Care
  • Exchange
  • MURA Nasdaq
  • NSPR Nasdaq
  • Market Cap
  • MURA N/A
  • NSPR 75.6M
  • IPO Year
  • MURA N/A
  • NSPR N/A
  • Fundamental
  • Price
  • MURA $1.26
  • NSPR $2.68
  • Analyst Decision
  • MURA Strong Buy
  • NSPR Strong Buy
  • Analyst Count
  • MURA 5
  • NSPR 2
  • Target Price
  • MURA $13.00
  • NSPR $4.75
  • AVG Volume (30 Days)
  • MURA 419.4K
  • NSPR 67.4K
  • Earning Date
  • MURA 03-11-2025
  • NSPR 03-12-2025
  • Dividend Yield
  • MURA N/A
  • NSPR N/A
  • EPS Growth
  • MURA N/A
  • NSPR N/A
  • EPS
  • MURA N/A
  • NSPR N/A
  • Revenue
  • MURA N/A
  • NSPR $7,009,000.00
  • Revenue This Year
  • MURA $79.64
  • NSPR $50.18
  • Revenue Next Year
  • MURA N/A
  • NSPR $159.56
  • P/E Ratio
  • MURA N/A
  • NSPR N/A
  • Revenue Growth
  • MURA N/A
  • NSPR 12.96
  • 52 Week Low
  • MURA $1.12
  • NSPR $1.81
  • 52 Week High
  • MURA $5.02
  • NSPR $3.80
  • Technical
  • Relative Strength Index (RSI)
  • MURA 19.38
  • NSPR 38.93
  • Support Level
  • MURA $3.77
  • NSPR $2.57
  • Resistance Level
  • MURA $4.35
  • NSPR $2.78
  • Average True Range (ATR)
  • MURA 0.26
  • NSPR 0.20
  • MACD
  • MURA -0.30
  • NSPR -0.02
  • Stochastic Oscillator
  • MURA 4.92
  • NSPR 15.82

About NSPR InspireMD Inc.

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

Share on Social Networks: